EU commits to benefits of proposed SPC waiver

European generics and biosimilars manufacturers should have a level playing field with their international counterparts and should not be disadvantaged by the European Union’s (EU’s) supplementary protection certificate (SPC) mechanism, according to Elżbieta Bieńkowska, European Commissioner of the directorate-general for the internal market, industry, entrepreneurship and small- and medium-sized enterprises (SMEs).